Skip to main content

Dr. ANDREA KASINSKI

Associate Professor
  • 765-496-1658
  • HANS B054B
akasinski@purdue.edu

Associated website(s):

Lab Website , Publications

Dr. ANDREA KASINSKI

PROFESSIONAL FACULTY RESEARCH

(Cancer and Molecular Biology) Identifying roles for microRNAs in cancer development and progression and using this knowledge for clinical applications.


BIO

Greater than 90% of the human genome is transcribed, yet the functional role for most transcripts is unknown. Many of these unknown transcripts fall into a class of RNAs referred to as non-coding RNAs. The general goal of the Kasinski Lab is to determine the molecular contribution of non-coding RNAs (microRNAs, lncRNA, circRNAs) in normal and disease cells, and to capitalize on this knowledge through developing RNA-based therapeutics. The current projects in the Kasinski lab are subdivided into the following:

Project 1: Ligand-mediated delivery of therapeutically relevant small RNAs

Project 2: Endogenous delivery of RNAs through secreted extracellular vesicles (ie. exosomes)

Project 3: High throughput screening for small molecule inhibitors that alter miRNA biogenesis

Project 4: Identification of miRNAs and protein-coding genes mediating drug resistance

Education and Training

  • 2003-2009 - PhD, Emory University
  • 2009-2013 - Postdoctoral Fellow, Yale University

Awards

  • 2018, Purdue University, Department of Biological Sciences’ Team Award
  • 2018, Purdue University, Seed for Success – for obtaining external sponsored award of $1 million or more, NIH-R01CA226259
  • 2018, Purdue University, Seed for Success – for obtaining external sponsored award of $1 million or more, NIH-R01CA205420
  • 2018, American Cancer Society, Research Scholar Awardee, gratefully declined
  • 2017, American Cancer Society, Research Scholar Awardee
  • 2015, Favorite Faculty Nominee, Purdue University
  • 2015, Student Loan Repayment Program, National Institutes of Health, National Cancer Institutes
  • 2013, Pathway to Independence Award, National Institutes of Health, National Cancer Institutes
  • 2013, Benjamin F. Trump Award, Aspen Cancer Conference
  • 2013, Aspen Cancer Fellow
  • 2012, Pilot Grant, Yale Center for Molecular Discovery
  • 2012, Student Loan Repayment Program, National Institutes of Health
  • 2012, Women in Cancer Research Scholar, American Association of Cancer Research
  • 2011, Postdoctoral Fellowship, American Cancer Society
  • 2010, Postdoctoral Fellowship, National Institutes of Health, National Cancer Institute
  • 2008, Graduate Student Research Festival, National Institutes of Health

Relevant Publications

  • Elshafie, N., do Nascimento, N., Lichti, N., Kasinski A.L., Childress, M., Santos, A. ( 2021 ) MicroRNA biomarkers in canine diffuse large B-cell lymphoma. Veterinary Pathology 2021 Jan;58(1):34-41
  • Li,  W., Wang, Y., Liu, R., Kasinski, A.L., Shen, H., Slack, F.J., and Tang, D.G. ( 2021 ) MicroRNA-34a (miR-34a): Potent Tumor Suppressor, Cancer Stem Cell Inhibitor and Potential Anti-Cancer Therapeutic , Frontiers in Cell and Developmental Biology, 9:640587.
  • Abdelaal, A.M., and Kasinski, A.L. ( 2021 ) Ligand-mediated delivery of RNAi-based therapeutics for the treatment of oncological diseases. Nucleic Acids Research Cancer, Jul 2-;3(3):zcabb030
  • Pal, A.S., Bains, M., Agredo, A., Kasinski A.L. ( 2020 ) Identification of microRNAs that promote erlotinib resistance in non-small cell lung cancer Biochemical Pharmacology 2020 Jul 16:114154
  • Li, C., Kasinski A.L. (2020) In vivo cancer-based functional genomics. Trends in Cancer 2020 Dec;6(12):1002-1017
  • Myoung, S., and Kasinski, A.L. ( 2019 ) MicroRNAs in Diseases and Disorders – Emerging Therapeutic Targets. Chapter 14: Strategies for safe and targeted delivery of microRNA therapeutics. Royal Society of Chemistry.  386-415 May 2019
  • Orellana E.A., Li, C., Lisevick, A., and Kasinski, A.L . (2019) Identification and validation of microRNAs that synergize with miR-34a – a basis for combinatorial microRNA therapeutics . Cell Cycle, July 2019, http://doi.org/10.1080/1538410...
  • Orellana, E.A., Abdelaal, A.H., Rangasamy, R., Tenneti, S., Myoung, S., Low, P.S., Kasinski, A.L. ( 2019 ) Enhancing microRNA activity through increased endosomal release mediated by nigericin. Molecular Therapy: Nucleic Acids, Vol 16, 505-518
  • Kasinski, A.L. ( 2019 ) Combatting PDAC with two tumor-targeting small RNAs. Oncotarget 2019; 10:5892-5893
  • Orellana, E.A., Kasinski, A.L. ( 2017 ) No vehicle, no problem . Oncotarget. 2017 Oct27;8(57):96470-96471
  • Rangasamy, L., Venkatesh, C., Kanduluru, A.K., Srinivasaro, M., Bandara, A. You, F., Orellana, E.A., Kasinski, A.L. , Low, P.S. (2017) New mechanism for release of endosomal contents: osmotic lysis via nigericin-mediated K + /H + exchange. Under review
  • Pal, A.S., Kasinski, A.L. (2017) Animal models to study microRNA function . Advances in Cancer Research 135:53-118
  • Orellana, E.A., Tenneti, S., Rangasamy, L., Lyle, L.T., Low, P.S., Kasinski, A.L. (2017) FolamiRs: Ligand-targeted, vehicle-free delivery of microRNAs for the treatment of cancer . Science Translational Medicine, August 2; 9(401):eaam9327
  • Gilbert-Ross, M., Konen, J., Koo, J., Shupe, J., Robinson, B.S., Wiles 4th, W.G., Huang, C., Martin, W.D., Behera, M., Smith, G.H., Hill, C.E., Rossi, M.R., Sica, G.L., Rupji, M., Chen, Z., Kowalski, J., Kasinski, A.L. , Ramalingam, S.S., Fu, H., Khuri, F.R., Zhou, W., Marcus, A.I. (2017) Targeting adhesion signaling in KRAS, LKB1 mutant lung adenocarcinoma . JCI Insight, March 9; 2(5):e90487
  • Orellana, E.A., Kasinski, A.L. (2016) Sulforhodamine B (SRB) assay in cell culture to investigate cell proliferation . Bio-Protocol, November 5; 6(21) pii:e1984
  • Orellana, E.A., Kasinski, A.L. (2015) MicroRNAs in cancer: A historical perspective on the path from discovery to therapy . Cancers, July 27; 7(3):1388-1405
  • Kasinski, A.L. , Kelnar, K., Stahlhut, C., Orellana, E., Zhao, J., Shimer, E., Dysart, S., Chen, X., Bader, A.G., Slack, F.J. (2015) A combinatorial microRNA therapeutics approach to suppressing non-small cell lung cancer . Oncogene, July; 34(27):3547-3555
  • Zeiger, E., Gollapudi, B., Aardema, M.J., Auerbach, S., Boverhof, D., Custer, L., Dedon, P., Honma, M., Ishida, S., Kasinski, A.L. , Kim, J.H., Manjanatha, M.G., Marlowe, J., Pfuhler, S., Pogribny, I., Slikker, W., Stankowski, Jr., L.F., Tanir, J.Y., Tice, R., van Benthem, J., White, P., Witt., K.L, Thybaud, V. (2015) Opportunities to integrate new approaches in genetic toxicology: An ILSI-HESI workshop report . Environmental and Molecular Mutagenesis, April; 56(3):277-285
  • Humphrey, S.E., Kasinski, A.L. (2015) RNA-guided CRISPR-Cas technologies for genome-scale investigation of disease processes . Journal of Hematology & Oncology, April 2; 8:31
  • *Adams, B.D., * Kasinski, A.L. , Slack, F.J. (2014) Aberrant regulation and function of microRNAs in cancer. Current Biology, August 18; 24(16):R762-R776 *co-first author
  • Kasinski, A. , Dong, X., Khuri, F.R., Boss, J., Fu, H. (2014) Transcriptional regulation of YWHAZ, the gene encoding 14-3-3ζ. PLoS One, April 1; 9(4):e93480
  • * Kasinski, A. , *Slack, F.J. (2013) Small RNAs deliver a blow to ovarian cancer . Cancer Discovery, Nov; 3(11):1220-1221 *co-corresponding authors
  • Kasinski, A.L. , Slack, F.J. (2013) Generation of mouse lung epethelial cells. Bio-Protocol, August 5; 3(15):e837
  • Kasinski, A.L., Slack, F.J. (2012) miRNA-34 prevents cancer initiation and progression in a therapeutically resistant K-ras and p53-induced mouse model of lung adenocarcinoma. Cancer Research, Nov 1; 72(21):5576-5587
  • Kasinski, A.L., Slack, F.J. (2012) Arresting the culprit: targeted antagomir delivery to sequester oncogenic miR-221 in HCC. Molecular Therapy – Nucleic Acids, March 20; 1(3):e12
  • Kasinski, A.L., Slack, F.J. (2011) M icroRNAs en route to the clinic: progress in validating and targeting miRNAs for cancer therapy. Nature Reviews Cancer, Nov 24; 11(12):849-864
  • Kim, M., Kasinski, A.L., Slack, F.J. (2011) MicroRNA therapeutics in pre-clinical cancer models. Lancet Oncology, Apr;12(4):319-321
  • Kasinski, A.L., Slack, F.J. (2010) Potential microRNA therapies targeting Ras, NF Κ B and p53 signaling. Current Opinion in Molecular Therapeutics, Apr; 12(2):147-157

Invited and Selected Presentations

  • Harvard Medical School Initiative for RNA Medicine, June 2022
  • RNA-mediated silencing, Barbados, January 2022
  • Decoding microRNA Mysteries in Health and Disease, University of Illinois College of Dentistry, September 2021
  • Purdue Women in Science Program, West Lafayette, IN, November 2020
  • Manchester University, North Manchester IN, September 2020
  • Indo-UK Conference on Current Innovations and Future of Therapeutic Developments, Virtual Conference, June 2020
  • mRNA Untranslated Regions in Gene Regulation, Development, and Disease, Barbados, January 2020
  • Roswell Park Cancer Institute, The University of Buffalo, Developmental Therapeutics Seminar Series, January 2020
  • Mahidol University, Bangkok Thailand, March 2019
  • Keynote Speaker, 19th Annual Fellow’s Colloquium, National Cancer Institute, Bethesda, MA, February 2019
  • 5 th Annual International Conference on Drug Discovery, Development and Lead Optimization, Boston MA, November 2019
  • Purdue Science Student Council, West Lafayette, IN October 2019
  • Purdue Center for Cancer Research, CIS series, West Lafayette IN, February 2019
  • Keynote, Purdue Relay for Life’s Hope Gala, West Lafayette, IN, February 2019
  • Biden Cancer Summit, Purdue 150th Anniversary Celebration, West Lafayette, IN, September 2018
  • Keynote, NSF-Funded Science Outreach, Carnegie Museum, Crawfordsville, IN, April 2018
  • FASEB SRC: Post-transcriptional control of gene expression, Scottsdale AZ, June 2018
  • Midwest Chromatin and Epigenetics Meeting, Purdue University, West Lafayette, IN, June 2018
  • University of Montreal, February 2018
  • 2nd International Aegean Conference on the Long and the Short of Non-Coding RNAs, Heraklion, Crete, Greece, June 9, 2017
  • 22nd Annual Meeting of the RNA Society, Prague, Czech Republic, May 30, 2017
  • American Association for Cancer Research Annual Meeting, Washington, DC, April 1, 2017
  • Keystone Symposia on Molecular and Cellular Biology, Banff, Alberta Canada, February 7, 2017
  • 6th International Symposium on Folate Receptors, Breckenridge, CO, September 19, 2016
  • American Association for Cancer Research Annual Meeting, New Orleans, LA, April 16, 2016
  • Experimental Biology, San Diego, April 5, 2016
  • 3rd Annual Summit on Thoracic Malignancies and Head and Neck Cancer, Puerto Rico, December 10, 2015
  • Keystone Symposia on Molecular and Cellular Biology, Denver, CO, June 7, 2015
  • microRNA as Biomarkers and Diagnostics, Cambridge, MA, March 16, 2015
  • 2nd Annual Lung Cancer Summit, Dallas, TX, December 12, 2014
  • microRNA World Conference, Boston, MA, October 27, 2014
  • Aspen Cancer Conference, Aspen, Co, July 15, 2013
  • NIH Lung SPORE Workshop, National Cancer Institute, Rockville, MD, July 11, 2013
  • Department of Molecular Pathology, MD Anderson Cancer Center, Houston Tx, April 5, 2013
  • Department of Clinical Cancer Prevention, MD Anderson Cancer Center, Houston Tx, March 26, 2013
  • Departments of Hematology and Medical Oncology, and Radiation Oncology, Emory University, Atlanta, Ga, March 13, 2013
  • Department of Biology, Purdue University, West Lafayette, IN, December 12, 2012
  • The 4 th Japanese Association for RNAi International Symposium, Hiroshima, Japan, August 30, 2012
  • Thoracic Oncology Board, Emory University, Atlanta GA, May 1, 2012
  • ILIS Health and Environmental Science Institute, Silver Springs MD, April 24, 2012
  • American Association of Cancer Research Annual Meeting, Chicago, IL, April 2, 2012
  • Eighth Annual microRNA in Human Disease and Development Meeting, Cambridge Healthtech, Cambridge, MA, March 12, 2012

Current Grant Funding

  • R01 NCI - CA205420 "Enhancing miRNA Therapeutics Through Combinatorial Targeting and Vehicle-Free Delivery"
  • R00 NCI - CA178091 "Identification and Therapeutic Application of miRNA Drivers in Lung Cancer"
  • RSG-17-198-01, American Cancer Society "Enhancing microRNA Therapeutics Through Vehicle-Free Delivery"

Purdue University Biological Sciences, 915 W. State Street, West Lafayette, IN 47907

Main Office: (765) 494-4408   Business Office: (765) 494-4764  Contact Us

© 2020 Purdue University | An equal access/equal opportunity university | Copyright Complaints

Trouble with this page? Disability-related accessibility issue? Please contact the College of Science Webmaster.

Maintained by Science IT